Diamine derivatives as inhibitors of leukotriene a4 hydrolase
Abstract
This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
Claims
exact text as granted — not AI-modified1 . A compound having Formula (I):
wherein:
R is i) the group
or
ii) the group
or
iii) an optionally substituted heteroaryl;
n 1 , n 2 , and n 3 are each independently 0 to 2;
r is 0 to 4;
q is 0 to 2;
R 1a , R 1b , R 1c , R 1d and R 1e are each independently hydrogen, —R 13 —OR 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)R 10 , alkyl, halo, haloalkyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
R 1v , R 1w , R 1x , R 1y and R 1z are each independently hydrogen or fluoro;
R 2 is hydrogen, alkyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclyalkyl;
or R 2 and R 7 , together with the nitrogens to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 2 and R 7 , together with the nitrogens to which they are attached and one of R 5a , R 5b and R 5c , form an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
or R 2 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
or R 2 and R 5b , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 2 and R 8 , together with the nitrogen and carbon to which they are attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl;
R 3 is a direct bond, —O—, —R 12 —O—, —O—R 12 —, —O—R 12 —O—, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
R 4 is a direct bond, —O—R 12a —, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
each R 5a , R 5b , R 5c , R 6a , R 6b and R 6c are each independently hydrogen, alkyl, haloalkyl or hydroxyalkyl;
or any one of R 5a and R 6a together, R 5b and R 6b together, and R 5c and R 6c together can be an oxo group;
or R 5a and R 5b , together with the carbons to which they are attached, form an optionally substituted 3- to 7-membered cycloalkyl;
or R 5a and R 5c , together with the carbons to which they are attached, form an optionally substituted 4- to 7-membered cycloalkyl;
or R 5b and R 6b , together with the carbon to which they are attached, form an optionally substituted 3- to 7-membered cycloalkyl;
R 7 is hydrogen, —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )C(═O)N(R 10 )R 11 , alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, or optionally substituted heterocyclylalkyl;
or R 7 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 7 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl and R 2 and R 5c , together with the nitrogen and carbon to which are they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 7 and R 5b , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 7 and R 5c , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
R 8 is hydrogen, alkyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, —R 13 —OR 10 , —R 13 —O—R 14 —C(═O)OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 14 —C(═O)OR 10 , —R 13 —C(═O)—R 13 —N(R 10 )R 11 , —R 13 —C(═O)—R 14 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), or —R 14 —S(═O) p R 10 (where p is 0, 1 or 2);
or R 8 is aralkyl optionally substituted with one or more substituents selected from the group consisting of halo, nitro, cyano, optionally substituted heteroaryl, hydroxyiminoalkyl, —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 13 —N(R 10 )R 11 , —R 13 —C(═O)N(R 10 )—R 14 —N(R 10 )R 11 , —R 13 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), —R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )C(═O)R 10 , —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )—R 13 —C(═O)OR 10 , —R 13 —N(R 10 )C(═O)—R 14 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )C(═O)R 10 , —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )—R 14 —N(R 10 )R 11 , —R 13 —N(R 10 )S(═O) t N(R 10 )R 11 (where t is 1 or 2), and —R 13 —O—R 14 —C(═O)OR 10 ;
each R 9 is independently —O—R 10 , alkyl, hydroxyalkyl, halo, haloalkyl, aryl or aralkyl;
each R 10 and R 11 is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
or R 10 and R 11 , together with the nitrogen to which they are attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl;
R 12 is an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
R 12a is an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
each R 13 is independently a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain; and
each R 14 is independently an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
as a single stereoisomer or as a mixture of stereoisomers;
or a pharmaceutically acceptable salt, solvate, polymorph, clathrate, ammonium ion, N-oxide or prodrug thereof.
2 . A compound according to claim 1 wherein R is the group
3 . A compound according to claim 2 wherein
R 1a is hydrogen, —R 13 —C(O)OR 10 , —R 13 —C(O)R 10 , alkyl, halo, haloalkyl, cyano, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl; and
R 1b , R 1c , R 1d and R 1e are each independently hydrogen or halo.
4 . A compound according to claim 2 wherein
R 1a is hydrogen, —R 13 —C(O)OR 10 , —R 13 —C(O)R 10 , alkyl, halo, haloalkyl, optionally substituted phenyl, furanyl, thienyl, thiazolyl, or optionally substituted oxazolyl; and
R 1b , R 1c , R 1d and R 1e are each hydrogen.
5 . A compound according to claim 1 wherein R is the group
6 . A compound according to claim 1 wherein R is an optionally substituted heteroaryl.
7 . A compound according to claim 6 wherein R is furanyl, oxazolyl, pyrazol, pyridinyl, triazolyl, thiazolyl, or benzothiazolyl, each of which is optionally substituted.
8 . A compound according to claim 1 wherein:
R 2 and R 7 , together with the nitrogens to which they are attached and one of R 5a , R 5b and R 5c , form an optionally substituted 6- to 10-membered bridged N-heterocyclyl.
9 . A compound according to claim 8 having the following formula (I-1):
10 . A compound according to claim 9 wherein:
R 3 is a direct bond, —O—, —R 12 —O—, —O—R 12 —, —O—R 12 —O—, or an optionally substituted straight or branched alkylene chain;
R 4 is a direct bond, —O—R 12a —, or an optionally substituted straight or branched alkylene chain;
R 8 is aralkyl optionally substituted with one or more substituents selected from the group consisting of —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 and —R 13 —C(═O)N(R 10 )R 11 ;
each R 9 is independently alkyl, halo or —O—R 10 ;
R 12 is an optionally substituted straight or branched alkylene chain;
R 12a is an optionally substituted straight or branched alkylene chain; and
each R 13 is a direct bond or an optionally substituted straight or branched alkylene chain.
11 . A compound according to claim 10 wherein:
r is 0;
R 3 is a direct bond, —O—, —R 12 —O—, —O—R 12 —, —O—R 12 —O—, or an alkylene chain;
R 4 is a direct bond, —O—R 12a —, or an optionally substituted straight or branched alkylene chain;
R 8 is benzyl substituted with one or more substituents selected from —R 13 —OR 10 and —R 13 —C(═O)OR 10 ;
R 10 is hydrogen, alkyl or optionally substituted aryl;
R 12 is C 1-6 alkylene; and
R 12a is methylene or ethylene.
12 . A compound according to claim 1 wherein:
R 2 and R 7 , together with the nitrogens to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl.
13 . A compound according to claim 12 having the following formula (I-2):
14 - 18 . (canceled)
19 . A compound according to claim 12 having the following formula (I-3):
20 . (canceled)
21 . (canceled)
22 . A compound according to claim 1 wherein:
R 2 is hydrogen, alkyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl and optionally substituted heterocyclyalkyl;
R 8 is selected from the group consisting of hydrogen, alkyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 14 —C(═O)OR 10 , —R 13 —C(═O)—R 14 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), and —R 14 —S(═O) p R 10 (where p is 0, 1 or 2);
or R 8 is aralkyl optionally substituted with one or more substituents selected from the group consisting of halo, nitro, cyano, optionally substituted heteroaryl, hydroxyiminoalkyl, —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 13 —N(R 10 )R 11 , —R 13 —C(═O)N(R 10 )—R 14 —N(R 10 )R 11 , —R 13 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), —R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )C(═O)R 10 , —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )—R 14 —C(═O)OR 10 , —R 13 —N(R 10 )C(═O)—R 14 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )C(═O)R 10 , —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )—R 14 —N(R 10 )R 11 , —R 13 —N(R 10 )S(═O) t N(R 10 )R 11 (where t is 1 or 2), and —R 13 —O—R 14 —C(═O)OR 10 ;
or R 2 and R 8 , together with the nitrogen to which they are attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl.
23 . (canceled)
24 . (canceled)
25 . A compound according to claim 1 wherein:
R 2 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
or R 2 and R 5b , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl.
26 . (canceled)
27 . (canceled)
28 . A compound according to claim 27 which is of formula (I-4) or formula (I-5):
29 . A compound according to claim 1 wherein:
R 7 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 7 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl and R 2 and R 5c , together with the nitrogen and carbon to which are they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 7 and R 5b , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 7 and R 5c , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl.
30 . (canceled)
31 . (canceled)
32 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1 .
33 . A method of treating a disease or disorder ameliorated by the inhibition of LTA 4 -h activity in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of compound of claim 1 .
34 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.